Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR1801-ADC in c-Met Expressing Solid Tumors
NCT03859752Phase 1Suspended
- Sponsor
- Open Innovation Partners
- Start
- Aug 2019
- Primary completion
- Jul 2023
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TR1801-ADC in solid tumor, sponsored by Open Innovation Partners. Primary endpoints: Safety and Tolerability (Adverse Events) at 4 years and Maximum Tolerated Dose at 3.5 years. Started Aug 2019; status: suspended.
02
Drugs
TR1801-ADC
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03859752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859752.